TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02613897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: Saxagliptin (Onglyza™) is approved by the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. The 5 mg dose will be used for this study as it is the dose that is routinely used in the clinic. In addition, this dose is used in the pivotal studies in the saxagliptin/dapagliflozin clinical program.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin (Farxiga) is approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Dapagliflozin (Farxiga) is also approved in the EU as an adjunct to diet and exercise to improve glycemic control in patients with T2DM for whom metformin use is considered inappropriate due to intolerance, and in combination with other glucose-lowering medicinal products when these, in combination with diet and exercise do not provide adequate glycemic control. The 10 mg dose was chosen for this study because it has been extensively studied in Phase 3 trials and has demonstrated a favorable benefit-risk profile. In addition, this dose is the most commonly used dose in most countries.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin (Farxiga) is approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Dapagliflozin (Farxiga) is also approved in the EU as an adjunct to diet and exercise to improve glycemic control in patients with T2DM for whom metformin use is considered inappropriate due to intolerance, and in combination with other glucose-lowering medicinal products when these, in combination with diet and exercise do not provide adequate glycemic control. The 10 mg dose was chosen for this study because it has been extensively studied in Phase 3 trials and has demonstrated a favorable benefit-risk profile. In addition, this dose is the most commonly used dose in most countries.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03808441

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ctDNA analysis
Description: Regular ctDNA analysis, which upon a decrease in mutant BRAF VAF (variant allele frequency) level of ≥80% the switch to N+I is triggered.
Study: NCT02083640

Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib Formulation Reference
Description: 125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 1, which is representative of the intended commercial hard gelatin capsule.

Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib Formulation Test
Description: 125 mg single dose of palbociclib formulation with 41 micrometer API particle size and dissolution level 1

Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib Formulation Test
Description: 125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 2
Study: NCT01192490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 5cc of 2% Lidocaine gel will be placed on the cervix and intra-cervically prior to placement of a Mirena

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lubricant
Description: KY Gel will be placed on the cervix and intra-cervically prior to placement of the Mirena
Study: NCT01899560

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measure lung and chest wall elastance with esophageal catheter
Description: Patients will be in supine position with 30-45° head of bed elevation. The cuff of the endotracheal tube will be transiently overinflated to 60 cmH2O to ensure there will be no air leaks. NMBA (cisatracurium) will be administrated \[9\]. The fraction of inspired oxygen (FiO2) will be adjusted for continuously monitored oxygen saturation (SpO2) between 90 to 94%. Patients will be ventilated in pressure control with 15 cmH2O of driving pressure.~A low flow pressure/volume curve from 0 to 40 cmH2O will be performed.

Intervention type: OTHER
Group type: OTHER
Intervention: non-invasive method for measuring the lung elastance
Description: by measuring volume recruited during a change of pressure (∆PEEP/∆EELV)
Study: NCT01744496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Patches will contain 4 mg / 24 h (20 cm\^2), 6 mg/ 24 h (30 cm\^2), or 8 mg /24 h (40 cm\^2) of Rotigotine. Application of study medication starts at the Baseline Visit. Rotigotine will be administered once daily starting at 4 mg / 24 h. Doses will then be up-titrated in weekly increments of 2 mg / 24 h until optimal or maximum dose (16 mg / 24 h) is reached and the Maintenance Period can be started. The duration of the Titration Period will vary from 1 to 7 weeks ± 3 days. The Maintenance Period will last 12 weeks ± 5 days. Thereafter, during the De-escalation Period, the dose of study medication will be decreased by 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patches match the size of active patches 20 cm\^2, 30 cm\^2, or 40 cm\^2 and will contain Placebo. Application of Placebo patches starts at the Baseline Visit. Placebo patches will be administered once daily starting with the equivalent of 4 mg / 24 h. Doses will then be up-titrated in weekly equivalents to 2 mg / 24 h until either optimal dose or maximum dose is reached. The maximum dose is the equivalent to 16 mg / 24 h. The duration of the Titration Period will vary from 1 to 7 weeks. The Maintenance Period will last 12 weeks ± 5 days. During the De-escalation Period, the dose of Placebo will be decreased by the equivalent to 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
Study: NCT04488172

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-vitamin supplementation
Description: Vitamin B6:100 mg/day Vitamin B9: 5 mg/day Vitamin D: 1000 IU/day Vitamin E: 400 IU/day Co-Q10: 100 mg/day
Study: NCT03190863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery combined with neurofeedback (MINF)
Description: 7 individuals with C6-C7 tetraplegia randomize in the experimental group consisting in motor imagery practice combined with visual neurofeedback (NF - i.e. performance of the imagined movement).~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions. After each imagined movement, the NF based on brain activity measured by electroencephalography is display on a screen.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor imagery (MI)
Description: 7 individuals with C6-C7 tetraplegia randomized in the active comparator group consisting in motor imagery practice alone without visual NF. This means that the performance of the imagined movement is not displayed to the participants.~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control (C)
Description: 7 individuals with C6-C7 tetraplegia randomized in the sham comparator group consisting in imagining geometric shapes by visualization. Shapes are successively displayed on a screen.~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions.
Study: NCT02099032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3g milk polar lipid fortified cheese consumption
Description: Women will have to consume daily 100g of a 3g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5g milk polar lipid fortified cheese consumption
Description: Women will have to consume daily 100g of a 5 g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Unfortified cheese product consumption
Description: Women will have to consume daily 100g of a unfortified cheese product instead of usual cheese products during four weeks
Study: NCT01831492

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zeolite + dolomite
Description: Given for 12 weeks, after a 4 weeks wash- out of all supplements/drugs

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cellulose
Description: given for 14 weeks
Study: NCT00906503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/Computed Tomography (CT)
Description: Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose (18F)
Description: Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
Study: NCT02800928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-501
Description: CERC-501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03415490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Folded technique of self-adherent wrap
Description: Wrapping a piece of self-adherent wrap around the patient's head starting with the opened end on the forehead above the affected eye.The bandage is then firmly but not tightly wrapped around the head twice. Then, after the second circuit, the bandage is brought on the cheek and up over the eye to the forehead, where it was passed between the eyebrows but not wrapped around the head. Instead, the bandage is folded and then first passed back on the cheek of the affected side then back to the forehead a total of four times. Finally, the bandage is wrapped completely around the head once

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic technique of self-adherent wrap
Description: Wrapping a piece of self-adherent wrap around the patient's head starting with the opened end on the forehead above the affected eye.The bandage is then firmly but not tightly wrapped around the head twice. After the second circuit, the bandage was brought below the ear, up over the eye and around the head of the non-affected side and then wrapped around the head in the same manner four times. The bandage is then brought around the head once.
Study: NCT00618670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Three times per week for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Three times per week for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control--Resistance Training
Description: Three times per week for 3 months
Study: NCT02244593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAST MRI and mammography screening
Description: Patients in this group will receive Breast MRI and annual mammography. Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram.
Study: NCT00482105

Intervention type: OTHER
Group type: OTHER
Intervention: EGIR Tape
Description: Tape stripping is a non-invasive method that allows the recovery of cells
Study: NCT04271592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H3733 Liquid Oral Dosage Form
Description: ABI-H3733 liquid oral dosage form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H3733 Liquid Oral Dosage Form
Description: ABI-H3733 liquid oral dosage form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H3733 Solid Oral Dosage Form
Description: ABI-H3733 solid oral dosage form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H3733 Solid Oral Dosage Form
Description: ABI-H3733 solid oral dosage form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to ABI-H3733 Liquid Oral Dosage Form
Description: Placebo to ABI-H3733 liquid oral dosage form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to ABI-H3733 Liquid Oral Dosage Form
Description: Placebo to ABI-H3733 liquid oral dosage form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to ABI-H3733 Solid Oral Dosage Form
Description: Placebo to ABI-H3733 solid oral dosage form
Study: NCT01455376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperosmolar sodium lactate
Description: Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
Study: NCT04271592

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to ABI-H3733 Solid Oral Dosage Form
Description: Placebo to ABI-H3733 solid oral dosage form
Study: NCT03896230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Injectable Product
Description: Three different doses of ketamine will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Injectable Product
Description: Three different doses of ketamine will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Injectable Product
Description: Three different doses of ketamine will be administered.
Study: NCT03272477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 12 weeks (4cycles) of max. 90mg/sqm in adjuvant therapy phase
Study: NCT00107185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Study: NCT02945774

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: (18F)-FEPPA
Description: PET ligand that binds to activated microglia, a marker of neuroinflammation
Study: NCT01225042

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo consisting of carrier material powder of identical appearance
Study: NCT02096081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: 20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: 20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
Study: NCT00421863

Intervention type: DRUG
Group type: OTHER
Intervention: Norvasc 10 mg
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).

Intervention type: DRUG
Group type: OTHER
Intervention: Norvasc 10 mg
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Study: NCT03505359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: partial knee immobilization protocol
Description: 12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength with a 0-60 degrees articulated knee brace in the first 6 weeks in the experimental group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard ACL reconstruction rehabilitation protocol
Description: 12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength.
Study: NCT02269618

Intervention type: OTHER
Group type: OTHER
Intervention: Home-based telehealth program
Description: Home-based telehealth program~* Scheduled calls initiated by nurse performed weekly; the nurse carried out a standardized interview on general clinical condition of the patients.~* Unscheduled calls initiated by patients or caregivers through the service centre(24h/24h) to report any clinical problems. in case of signs or symptoms~* Telemonitoring: during calls, patients can transmit via landline or mobile phone the recordings from the 1-lead ECG to a service centre, and talk to the nurse or doctor~* Home visit performed by therapist seven days after hospital discharge by setting the daily physical activity and other home visits in case of need~* Scheduled calls initiated by therapist performed weekly aimed at increasing workload and evaluating the proper execution of exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: Home-based rehabilitation
Description: Home-based rehabilitation Individual rehabilitative program including at least 3 sessions/week of mini-ergometer and exercises and 2 sessions/week of walking with pedometer~* Mini-ergometer: The personalized protocol will be structured at the beginning on the basis of data obtained from the assessment of the baseline exercise test, trying to get a training activity to the maximum value of around a Borg dyspnoea and motor equal to 6 (according to the protocol of Maltais)~* Walking: The patient will be encouraged to walk every day. Will be given a pedometer and will be asked to try to increase the amount of steps up to the maximal for the patient.
Study: NCT00421863

Intervention type: DRUG
Group type: OTHER
Intervention: Triatec 5 mg
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).

Intervention type: DRUG
Group type: OTHER
Intervention: Triatec 5 mg
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Study: NCT03272477

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery at week 14 after randomization (or later, if neoadjuvant phase is prolonged)
Study: NCT01564654

Intervention type: DEVICE
Intervention: iTotal KRS
Description: Total Knee Replacement System
Study: NCT00421863

Intervention type: DRUG
Group type: OTHER
Intervention: Pluscor
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).

Intervention type: DRUG
Group type: OTHER
Intervention: Pluscor
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Study: NCT01868243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Group 1 - Dabigatran 110 mg (50 patients)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin adjusted-dose
Study: NCT04406545

Intervention type: OTHER
Intervention: evaluation of skin microvascular flow and reactivity
Description: evaluation of skin microvascular flow and reactivity using laser Doppler perfusion monitoring

Intervention type: OTHER
Intervention: evaluation of skin microvascular flow and reactivity
Description: evaluation of skin microvascular flow and reactivity using laser Doppler perfusion monitoring
Study: NCT04190160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDegLira
Description: A single administration of IDegLira, dose depending on glicaemic control, in place of any pre-existing hipoglycaemic therapeutic scheme
Study: NCT04511845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPYK04
Description: SPYK04 capsule
Study: NCT03808714

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TOUCHDOWN
Description: We expect the intervention to consist of 3 to 4 group sessions and at least one individual session plus pharmacological consultation(s) via Skype, but this will be determined during pretesting. CHWs will have IPads with cellular connectivity and will be present when the pharmacological approach is discussed with the participant so that they can reinforce the message with the participant and be the liaisons between the participant and physician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Alabama Quitline
Study: NCT02270632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F8IL10
Description: F8IL10 will be administered once a week for 8 weeks (or until withdrawn from the study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F8IL10
Description: F8IL10 will be administered once a week for 8 weeks (or until withdrawn from the study).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: All patients enrolled in the study will receive as concomitant therapy MTX at stable dose (10-25 mg/week), and the corresponding fixed dose of folic acid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: All patients enrolled in the study will receive as concomitant therapy MTX at stable dose (10-25 mg/week), and the corresponding fixed dose of folic acid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: All patients enrolled in the study will receive as concomitant therapy MTX at stable dose (10-25 mg/week), and the corresponding fixed dose of folic acid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once a week for 8 weeks (or until withdrawn from the study).
Study: NCT03851744

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sea Level
Description: Carbohydrate consumed at 1.8 g/min during treadmill exercise at SL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Altitude
Description: Carbohydrate consumed at 1.8 g/min during treadmill exercise at HA
Study: NCT01663740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Participants will receive valganciclovir 900 milligrams (mg) orally once daily for up to a maximum of 200 days post-transplant.
Study: NCT00530712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROTÉGÉ® EverFlex™ Self-Expanding Stent System
Description: Implantation of a single study device in the native superficial femoral artery or superficial femoral artery and proximal popliteal artery.
Study: NCT02573805

Intervention type: DEVICE
Intervention: Rigiscan test
Description: Rigiscan tests are performed in enrolled subjects for consecutive two nights.

Intervention type: DEVICE
Intervention: Rigiscan test
Description: Rigiscan tests are performed in enrolled subjects for consecutive two nights.
Study: NCT01795040

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3/omega-6 fatty acids (PUFAs)
Description: Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: omega-3/omega-6 fatty acids (PUFAs)
Description: Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid